The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) induces regression in papillary renal cell carcinoma patient-derived xenograft models

Clinical Cancer Research

Volumn 21, Issue 12, 2015, Pages 2811-2819

  Schuller, Alwin G ^a   Barry, Evan R ^a   Jones, Rhys D O ^b   Henry, Ryan E ^a   Frigault, Melanie M ^a   Beran, Garry ^b   Linsenmayer, David ^a   Hattersley, Maureen ^a   Smith, Aaron ^b   Wilson, Joanne ^b   Cairo, Stefano ^c   Deas, Olivier ^c   Nicolle, Delphine ^c   Adam, Ammar ^a   Zinda, Michael ^a   Reimer, Corinne ^a   Fawell, Stephen E ^a   Clark, Edwin A ^a   D'Cruz, Celina M ^a  

^a Oncology Innovative Medicines Astra Zeneca ^*  (United States)

^b ASTRAZENECA   (United Kingdom)

^c XenTech   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; SAVOLITINIB; SUNITINIB; 1-(1-(IMIDAZO(1,2-A)PYRIDIN-6-YL)ETHYL)-6-(1-METHYL-1H-PYRAZOL-4-YL)-1H-(1,2,3)TRIAZOLO(4,5-B)PYRAZINE; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; MET PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PYRAZINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRROLE DERIVATIVE; SCATTER FACTOR RECEPTOR; TRIAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER MODEL; CANCER REGRESSION; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; FEMALE; GENE DOSAGE; GENE MUTATION; IN VIVO STUDY; KIDNEY CARCINOMA; MOUSE; NONHUMAN; PAPILLARY CARCINOMA; PHARMACODYNAMICS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, PAPILLARY; CARCINOMA, RENAL CELL; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; GENETICS; HUMAN; METABOLISM; PATHOLOGY; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, PAPILLARY; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INDOLES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; PYRAZINES; PYRAZOLES; PYRIDINES; PYRROLES; TRIAZINES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84937457062     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2685     Document Type: Article

References (36)

1. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF.Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915-25.
2. Corso S, Comoglio PM, Giordano S. Cancer therapy: can the challenge be MET? Trends Mol Med 2005;11:284-92.
3. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. TargetingMETin cancer: rationale and progress. Nat Rev Cancer 2012;12:89-103.
4. Giubellino A, Linehan WM, Bottaro DP. Targeting the Met signaling pathway in renal cancer. Expert Rev Anticancer Ther 2009;9:785-93.
5. Tanizaki J, Okamoto I, Sakai K, Nakagawa K. Differential roles of transphosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification. Br J Cancer 2011; 105:807-13.
6. Chow WH, Devesa SS. Contemporary epidemiology of renal cell cancer. Cancer J 2008;14:288-301.
7. Kovacs G. Molecular cytogenetics of renal cell tumors. Adv Cancer Res 1993;62:89-124.
8. Lubensky IA, Schmidt L, Zhuang Z, Weirich G, Pack S, Zambrano N, et al. Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. Am J Pathol 1999; 155:517-26.
9. Albiges L, Guegan J, Le Formal A, Verkarre V, Rioux-Leclercq N, Sibony M, et al. MET is a potential target across all papillary renal cell carcinomas: result from a largemolecular study of pRCC with CGH array and matching gene expression array. Clin Cancer Res 2014;20:3411-21.
10. Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: An expanded-Access trial. Lancet Oncol 2009;10:757-63.
11. Jia H, Dai G, Weng J, Zhang Z, Wang Q, Zhou F, et al. Discovery of (S)-1-(1-(Imidazo[1, 2-A]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1, 2, 3]triazolo[4, 5-b]pyrazine (volitinib) as a highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitor in clinical development for treatment of cancer. J Med Chem 2014;57:7577-89.
12. Gavine PR, Ren Y, Han L, Lv J, Fan S, Zhang W, et al. Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models. Mol Oncol 2015;9:323-33.
13. Glukhova L, Goguel AF, Chudoba I, Angevin E, Pavon C, Terrier-Lacombe MJ, et al. Overrepresentation of 7q31 and 17q in renal cell carcinomas. Genes Chromosomes Cancer 1998;22:171-8.
14. Shojaei F, Lee JH, Simmons BH, Wong A, Esparza CO, Plumlee PA, et al. HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Cancer Res 2010;70:10090-100.
15. Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-Analysis. Cancer Chemother Pharmacol 2010;66:357-71.
16. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-37.
17. Zhou Q, Gallo JM. Quantification of sunitinib in mouse plasma, brain tumor and normal brain using liquid chromatography-electrospray ionization-Tandem mass spectrometry and pharmacokinetic application. J Pharm Biomed Anal 2010;51:958-64.
18. Haznedar JO, Patyna S, Bello CL, Peng GW, Speed W, Yu X, et al. Single-And multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in nonclinical species. Cancer Chemother Pharmacol 2009;64:691-706.
19. Timm A, Kolesar JM. Crizotinib for the treatment of non-small-cell lung cancer. Am J Health Syst Pharm 2013;70:943-7.
20. Yamazaki S, Skaptason J, Romero D, Lee JH, Zou HY, Christensen JG, et al. Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available cMet kinase inhibitor in human tumor xenograft mouse models. Drug Metab Dispos 2008; 36:1267-74.
21. Yamazaki S, Skaptason J, Romero D, Vekich S, Jones HM, Tan W, et al. Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one-compartment model. Drug Metab Dispos 2011;39:383-93.
22. Hui Kong Gan JL, Michael Millward, Yi Gu, Weiguo SU, Melanie Frigault, Chuan Qi, et al. First-in-human phase I study of a selective c-Met inhibitor volitinib (HMP504/AZD6094) in patients with advanced solid tumors. J Clin Oncol 2014;32:(suppl; abstr 11111).
23. Lai AZ, Cory S, Zhao H, Gigoux M, Monast A, Guiot MC, et al. Dynamic reprogramming of signaling upon met inhibition reveals a mechanism of drug resistance in gastric cancer. Sci Signal 2014;7:ra38.
24. Shattuck DL, Miller JK, Carraway KL III, Sweeney C. Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res 2008;68:1471-7.
25. Dulak AM, Gubish CT, Stabile LP, Henry C, Siegfried JM. HGF-independent potentiation of EGFR action by c-Met. Oncogene 2011;30: 3625-35.
26. Glukhova L, Lavialle C, Fauvet D, Chudoba I, Danglot G, Angevin E, et al. Mapping of the 7q31 subregion common to the small chromosome 7 derivatives from two sporadic papillary renal cell carcinomas: increased copy number and overexpression of the MET proto-oncogene. Oncogene 2000;19:754-61.
27. Shojaei F, Simmons BH, Lee JH, Lappin PB, Christensen JG. HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell typedependent metastasis. Cancer Lett 2012;320:48-55.
28. Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol 2013;31:181-6.
29. Diamond JR, Salgia R, Varella-Garcia M, Kanteti R, LoRusso PM, Clark JW, et al. Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma. J Clin Oncol 2013;31: e254-8.
30. Gavine PR, Ren Y, Han L, Lv J, Fan S, Zhang W, et al. Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in gastric cancer patient-derived tumor xenograft models. Mol Oncol 2015;9:323-33.
31. Yumin Cui GD, Ren Yongxin, Zhou Feng, Fan Shiming, Sai Yang, Gu Yi, et al. A novel and selective c-Met inhibitor against subcutaneous xenograft and othotopic brain tumor models. Cancer Res 2011;71.
32. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-43.
33. Van Emburgh BO, Sartore-Bianchi A, DiNicolantonio F, Siena S, Bardelli A. Acquired resistance to EGFR-Targeted therapies in colorectal cancer. Mol Oncol 2014;8:1084-94.
34. Bardelli A, Corso S, Bertotti A, Hobor S, Valtorta E, Siravegna G, et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov 2013;3:658-73.
35. Mariani M, McHughM, Petrillo M, Sieber S, He S, Andreoli M, et al. HGF/c-Met axis drives cancer aggressiveness in the neo-Adjuvant setting of ovarian cancer. Oncotarget 2014;5:4855-67.
36. Ruco L, Scarpino S. The pathogenetic role of the HGF/c-Met system in papillary carcinoma of the thyroid. Biomedicines 2014;2:263-74.